Jakavi (USD 48 million) grew as an oral inhibitor of the JAK 1 and JAK 2 tyrosine kinases. It is the first JAK inhibitor indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis. Jakavi (ruxolitinib) is currently approved in more than 50 countries, including EU member states, Canada, Australia, Mexico and Argentina, with additional regulatory filings underway. Novartis licensed ruxolitinib from Incyte Corporation for development and commercialization outside the US.
Sales 48 vs 35 means up 13 on 35 equals a qtr increase of 37%. Thirty seven percent increase in a quarter equals one hundred and fifty percent annualized. Is this how fast sales are growing? Is this reflected in the price? Seems like really good news to me.